Literature DB >> 1334806

Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation by dexamethasone, isoproterenol, or prostaglandin E2 either alone or in combination.

L Elliott1, W Brooks, T Roszman.   

Abstract

1. The purpose of these studies was to investigate the modulation of the proliferation of human T cells obtained from peripheral blood by dexamethasone (DEX), isoproterenol (ISO), and prostaglandin E2 (PGE2). The former two substances interact with T cells via the glucocorticoid and beta-adrenergic receptors respectively. When occupied by their natural ligands, glucocorticosteroids and catecholamines, these receptors have a role in modulating T-cell function during stress. During the inflammatory response increased levels of PGE2 bind to their receptors on T cells and thus alter responsiveness. Proliferation of T cells was induced by immobilized anti-CD3 monoclonal antibody (mAb) in the presence or absence of an additional costimulatory signal delivered by anti-CD28 mAb. 2. Various physiologic concentrations of DEX, ISO, or PGE2 were added at the time of initiation of the cultures and subsequent proliferation of the unstimulated T cells was determined. The results demonstrate that physiologic concentrations of all three of these agents inhibit the anti-CD3 mAb-induced proliferation of T cells. 3. Although DEX and PGE2 were equipotent in suppressing T-cell proliferation, ISO was much less effective. 4. Because concomitant elevations in the peripheral levels of these substances may occur, experiments were performed to determine the T-cell inhibitory effects of DEX together with either PGE2 or ISO. Synergistic suppression of T-cell proliferation was observed when various concentrations of DEX and PGE2, but not DEX and ISO, were added to cultures. This synergistic suppression could not be explained by an increase in cAMP accumulation in T cells stimulated with DEX and PGE2. 5. Finally, the addition of anti-CD28 mAb to anti-CD3 mAb-stimulated T cells overcame much of the suppression of proliferation induced by PGE2 or ISO but less so than that induced by DEX.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334806     DOI: 10.1007/bf00711542

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  39 in total

1.  Direct helper T cell-induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7.

Authors:  N K Damle; P S Linsley; J A Ledbetter
Journal:  Eur J Immunol       Date:  1991-05       Impact factor: 5.532

2.  Glucocorticoid receptors in purified subpopulations of human peripheral blood lymphocytes.

Authors:  M Lippman; R Barr
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  Modulation of catecholamine activation of adenylate cyclase by the number of active beta-adrenergic receptors: theoretical considerations on the role of receptor diffusion in the cell membrane.

Authors:  S Swillens
Journal:  J Cyclic Nucleotide Res       Date:  1982

5.  T cell receptor tyrosine phosphorylation. Variable coupling for different activating ligands.

Authors:  R D Klausner; J J O'Shea; H Luong; P Ross; J A Bluestone; L E Samelson
Journal:  J Biol Chem       Date:  1987-09-15       Impact factor: 5.157

6.  T cell CD3-zeta eta heterodimer expression and coupling to phosphoinositide hydrolysis.

Authors:  M Merćep; J S Bonifacino; P Garcia-Morales; L E Samelson; R D Klausner; J D Ashwell
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

Review 7.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; J Ceuppens
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

Review 8.  Stress hormones: their interaction and regulation.

Authors:  J Axelrod; T D Reisine
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

9.  Beta adrenergic receptors in lymphocyte subpopulations.

Authors:  N H Bishopric; H J Cohen; R J Lefkowitz
Journal:  J Allergy Clin Immunol       Date:  1980-01       Impact factor: 10.793

10.  Regulation of fibronectin biosynthesis by dexamethasone, transforming growth factor beta, and cAMP in human cell lines.

Authors:  D C Dean; R F Newby; S Bourgeois
Journal:  J Cell Biol       Date:  1988-06       Impact factor: 10.539

View more
  6 in total

1.  Relative quantification of beta-adrenergic receptor in peripheral blood cells using flow cytometry.

Authors:  Didem Saygin; Nicholas Wanner; Jonathan A Rose; Sathyamangla V Naga Prasad; W H Wilson Tang; Serpil Erzurum; Kewal Asosingh
Journal:  Cytometry A       Date:  2018-03-24       Impact factor: 4.355

Review 2.  Beta2-Adrenoceptor Agonists in Parkinson's Disease and Other Synucleinopathies.

Authors:  Luca Magistrelli; Cristoforo Comi
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-07       Impact factor: 4.147

3.  Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex.

Authors:  Georgialina Rodriguez; Jeremy A Ross; Zsuzsanna S Nagy; Robert A Kirken
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

4.  An EP receptor with a novel pharmacological profile in the T-cell line Jurkat.

Authors:  G W De Vries; P Guarino; A McLaughlin; J Chen; S Andrews; D F Woodward
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

Review 5.  Combating immunosuppression in glioma.

Authors:  Eleanor A Vega; Michael W Graner; John H Sampson
Journal:  Future Oncol       Date:  2008-06       Impact factor: 3.404

6.  Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation and interleukin-2 secretion by physiologic combinations of dexamethasone and prostaglandin E2.

Authors:  L Elliott; W Brooks; T Roszman
Journal:  Cell Mol Neurobiol       Date:  1993-12       Impact factor: 5.046

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.